Zymeworks Inc.

By person

11 insiders · 68 transactions

7.8×

Kenneth Galbraith holds 7.8 times base salary in stock. $5.14M of shares against $654.83K in salary for 2024.

Salary from the company's own proxy. The shares are what Kenneth Galbraith last reported holding, valued at $22.67, the price Common Stock was last bought or sold at on the open market here, on 12 Jan 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

EcoR1 Capital, LLC entity

Director

$89.85M (42)

—

+$89.85M

22,970,388

32.37%

$520.82M

+160.3%

Galbraith Kenneth

Chair & CEO

—

$4.45M (8) scheduled

−$4.45M

226,842

0.3197%

$5.14M

—

Moore Paul Andrew

Chief Scientific Officer

—

$1.14M (7) scheduled

−$1.14M

48,497

0.0683%

$1.10M

—

Smith Jeffrey T L

EVP & Chief Medical Officer

—

$641.37K (3) scheduled

−$641.37K

26,708

0.0376%

$605.56K

—

Hollywood Mark

EVP & Chief Operating Officer

—

$138.76K (1) scheduled

−$138.76K

133,852

0.1886%

$3.03M

+10.3%

Astle Christopher

SVP & Chief Financial Officer

—

$78.08K (4) scheduled

−$78.08K

6,503

0.0092%

$147.45K

+870.6%

Klompas Neil A

President & COO

—

$23.30K (1) scheduled

−$23.30K

17,032

0.0240%

$386.18K

+15.1%

Josephson Neil

Chief Medical Officer

—

$20.05K (1) scheduled

−$20.05K

14,449

0.0204%

$327.61K

+30.9%

Redmile Group, LLC entity

10% owner

—

6,075,918

8.56%

$137.76M

+0.5%

Ciongoli Gregory Austin

Director

—

488,500

0.6884%

$11.08M

+564.6%

PATTERSON LEONE D

EVP, Chief Bus & Fin Officer

—

459

0.0006%

$10.41K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Galbraith Kenneth

12 Jan 2026

Chair & CEO

Sold after exercise

30,424

$22.67

$689.82K

Moore Paul Andrew

12 Jan 2026

Chief Scientific Officer

Sold after exercise

9,560

$22.67

$216.76K

Smith Jeffrey T L

12 Jan 2026

EVP & Chief Medical Officer

Sold after exercise

9,310

$22.67

$211.09K

Hollywood Mark

12 Jan 2026

EVP & Chief Operating Officer

Sold after exercise

6,120

$22.67

$138.76K

Moore Paul Andrew

5 Jan 2026

Chief Scientific Officer

Sold after exercise

10,821

$25.10

$271.57K

Moore Paul Andrew

5 Jan 2026

Chief Scientific Officer

Sold after exercise

9,289

$25.10

$233.13K

Galbraith Kenneth

5 Jan 2026

Chair & CEO

Sold after exercise

31,686

$25.10

$795.22K

Galbraith Kenneth

5 Jan 2026

Chair & CEO

Sold after exercise

22,657

$25.10

$568.62K

Smith Jeffrey T L

5 Jan 2026

EVP & Chief Medical Officer

Sold after exercise

10,538

$25.10

$264.47K

Galbraith Kenneth

22 Dec 2025

Chair & CEO

Sold after exercise

47,528

$27.02

$1.28M

Smith Jeffrey T L

6 Jan 2025

EVP & Chief Medical Officer

Sold after exercise

11,110

$14.92

$165.81K

Galbraith Kenneth

6 Jan 2025

Chair & CEO

Sold after exercise

33,406

$14.92

$498.55K

Galbraith Kenneth

6 Jan 2025

Chair & CEO

Sold after exercise

23,885

$14.92

$356.46K

Moore Paul Andrew

6 Jan 2025

Chief Scientific Officer

Sold after exercise

11,408

$14.92

$170.25K

Moore Paul Andrew

6 Jan 2025

Chief Scientific Officer

Sold after exercise

9,792

$14.92

$146.14K

Moore Paul Andrew

5 Jan 2024

Chief Scientific Officer

Sold after exercise

7,460

$10.65

$79.47K

Astle Christopher

5 Jan 2024

SVP & Chief Financial Officer

Sold after exercise

4,563

$10.65

$48.61K

Galbraith Kenneth

5 Jan 2024

Chair & CEO

Sold after exercise

18,198

$10.65

$193.85K

Astle Christopher

11 Dec 2023

SVP & Chief Financial Officer

Sold after exercise

886

$9.13

$8.09K

Klompas Neil A

10 Mar 2023

President & COO

Sold after exercise

2,977

$7.83

$23.30K

Astle Christopher

12 Dec 2022

SVP & Chief Financial Officer

Sold after exercise

887

$6.01

$5.33K

Josephson Neil

10 Nov 2022

Chief Medical Officer

Sold after exercise

2,475

$8.10

$20.05K

Show all 68 transactions →

By person

Individual transactions

What was left out